HRTX HERON THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, HERON THERAPEUTICS INC reported revenue of $37.7M (up 1.3% from a year earlier), net income of −$5.49M and diluted EPS of −$0.03; over the last four quarters revenue was $151M and net income −$33.9M; for the fiscal year ended December 2025 revenue was $155M, up 7.4% on the year before.
HRTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $155M, gross profit $114M, operating income −$2.54M, net income −$20.0M (margin -12.9%), EPS −$0.12
- Fiscal year ended Dec 2024: revenue $144M, gross profit $106M, operating income −$11.5M, net income −$14.0M (margin -9.7%), EPS −$0.09
- Fiscal year ended Dec 2023: revenue $127M, gross profit $61.9M, operating income −$111M, net income −$111M (margin -87.4%), EPS −$0.80
- Fiscal year ended Dec 2022: revenue $108M, gross profit $52.8M, operating income −$175M, net income −$182M (margin -169.0%), EPS −$1.67
- Fiscal year ended Dec 2021: revenue $86.3M, gross profit n/a, operating income −$218M, net income −$221M (margin -255.9%), EPS −$2.24
HRTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $37.7M (up 1.3% year over year), net income −$5.49M, EPS −$0.03
- Quarter ended Mar 31, 2026: revenue $34.7M (down 10.8% year over year), net income −$8.11M, EPS −$0.04
- Quarter ended Dec 31, 2025 (from the annual report): revenue $40.6M (down 0.5% year over year), net income −$2.76M, EPS −$0.01
- Quarter ended Sep 30, 2025: revenue $38.2M (up 16.5% year over year), net income −$17.5M, EPS −$0.10
- Quarter ended Jun 30, 2025: revenue $37.2M (up 3.3% year over year), net income −$2.38M, EPS −$0.02
- Quarter ended Mar 31, 2025: revenue $38.9M (up 12.2% year over year), net income $2.64M, EPS $0.01
- Quarter ended Dec 31, 2024 (from the annual report): revenue $40.8M (up 19.1% year over year), net income $3.24M, EPS $0.02
- Quarter ended Sep 30, 2024: revenue $32.8M (up 4.4% year over year), net income −$4.85M, EPS −$0.03
- Quarter ended Jun 30, 2024: revenue $36.0M (up 13.4% year over year), net income −$9.24M, EPS −$0.06
- Quarter ended Mar 31, 2024: revenue $34.7M (up 17.1% year over year), net income −$3.16M, EPS −$0.02
- Quarter ended Dec 31, 2023 (from the annual report): revenue $34.2M (up 14.0% year over year), net income −$11.2M, EPS −$0.01
- Quarter ended Sep 30, 2023: revenue $31.4M (up 18.4% year over year), net income −$25.0M, EPS −$0.17
- Quarter ended Jun 30, 2023: revenue $31.8M (up 15.0% year over year), net income −$42.1M, EPS −$0.35
- Quarter ended Mar 31, 2023: revenue $29.6M (up 26.3% year over year), net income −$32.8M, EPS −$0.27
- Quarter ended Dec 31, 2022 (from the annual report): revenue $30.0M (up 45.4% year over year), net income −$19.8M, EPS −$0.11
- Quarter ended Sep 30, 2022: revenue $26.6M (up 14.3% year over year), net income −$41.9M, EPS −$0.38
- Quarter ended Jun 30, 2022: revenue $27.6M (up 23.1% year over year), net income −$56.4M, EPS −$0.55
- Quarter ended Mar 31, 2022: revenue $23.5M (up 17.2% year over year), net income −$63.9M, EPS −$0.63
- Quarter ended Dec 31, 2021 (from the annual report): revenue $20.7M, net income −$55.0M, EPS −$0.53
- Quarter ended Sep 30, 2021: revenue $23.2M, net income −$52.4M, EPS −$0.51
HRTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$27.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$22.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$58.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$147M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$203M, share buybacks n/a
HRTX balance sheet
- Jun 30, 2026: cash $20.7M, total assets $252M, total liabilities $245M, shareholders' equity $6.91M
- Mar 31, 2026: cash $26.1M, total assets $246M, total liabilities $237M, shareholders' equity $9.14M
- Dec 31, 2025: cash $28.6M, total assets $256M, total liabilities $242M, shareholders' equity $14.3M
- Sep 30, 2025: cash $43.1M, total assets $249M, total liabilities $234M, shareholders' equity $14.9M
- Jun 30, 2025: cash $16.5M, total assets $232M, total liabilities $259M, shareholders' equity −$27.3M
- Mar 31, 2025: cash $19.3M, total assets $236M, total liabilities $264M, shareholders' equity −$28.5M
- Dec 31, 2024: cash $25.8M, total assets $233M, total liabilities $267M, shareholders' equity −$33.7M
- Sep 30, 2024: cash $25.7M, total assets $221M, total liabilities $261M, shareholders' equity −$40.0M
What is HRTX's revenue?
HERON THERAPEUTICS INC reported $151M of revenue over its last four quarters, through June 30, 2026.
Is HRTX profitable?
No. HERON THERAPEUTICS INC lost $33.9M over the last four quarters.
What is HRTX's EPS?
Diluted earnings per share over the last four quarters were −$0.18; −$0.03 in the latest quarter.